
The number of diagnosed chronic hepatitis C cases is expected to rise modestly across eight major pharmaceutical markets over the next decade, reaching 7.46 million by 2035, according to UK data and analytics company GlobalData (LSE: DATA).
GlobalData’s latest Hepatitis C Virus: Epidemiology Forecast to 2035 report predicts diagnosed prevalent cases will increase from 7.19 million in 2025 to 7.46 million in 2035, an annual growth rate of 0.4%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze